Buscar
Mostrando ítems 1-4 de 4
Artículo
Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis
(Frontiers Media SA, 2021)
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to ...
Artículo
Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
(Elsevier Science BV, 2022)
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), ...
Artículo
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
(Oxford University Press, 2022-07-27)
Background Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation ...
Artículo
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
(Elsevier, 2022-08-19)
Background Cardiometabolic dysfunction is common in young people with psychosis. Recently, the Psychosis Metabolic Risk Calculator (PsyMetRiC) was developed and externally validated in the UK, predicting up-to six-year ...